Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| Pre-IDE I060071 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Comparing the new Stainless Steel WaterWorks® douching device to a commercially available douching device using just water for safety and efficacy of odor abatement.
Vaginal symptoms, including abnormal odor with or without complaints of discharge, are relatively common complaints. It is generally assumed that most women with these complaints have a vaginal infection, bacterial vaginosis, trichomoniasis, or vulvovaginal candidiasis. However, investigators suggest that there is a large population of women who complain of odor with or without complaints of discharge, and in whom no clear cause can be found. For these women, there are currently no treatment options.
Anecdotal evidence suggests that stainless steel used with just water has an effect in reducing odors and is so used to reduce odors on hands by chefs. The Water Works® Douching Device is a light-weight (1oz) stainless steel douching device that was developed to aid in the treatment of vaginal odor. Additional anecdotal evidence suggests that douching with the Water Works® Douching Device had little or no affect on the vaginal Eco-System (e.g. good bacteria, Lactobacilli).
This study (ARG105B) will compare the Water Works® Douching Device to a commercially available over the counter douching device for the ability to reduce or eliminate abnormal odor (with or without complaints of discharge) in women with this subjective complaint, but no objective findings of a vaginal infection. The study will also compare the Water Works® Douching Device to the commercial device with respect to the adverse effect of the vaginal Eco-System.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| WaterWorks Douching Device | Device |
| Measure | Description | Time Frame |
|---|---|---|
| The primary endpoint of the study is the reduction or abatement of the | ||
| subject's perceived vaginal odor as determined at Visit 3. | ||
| This improvement will be measured using a visual analog scale that | ||
| asks subjects to rate their perception of vaginal odor on a scale that | ||
| is anchored at two extremes, "no odor", and, "strong offensive odor". |
| Measure | Description | Time Frame |
|---|---|---|
| Effects on the vaginal Eco-System will be assessed using the | ||
| Lactobacilli score and the Nugent score. The safety profile of the douching | ||
| device (Water Works® versus control) will be assessed through the collection |
Not provided
Inclusion Criteria:
Enrollment in the study will be open to those subjects who meet the following inclusion criteria:
Exclusion Criteria:
Subjects will be excluded from the enrollment if they have any of the following:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ashwin Chatwani, M.D. | Temple University | Principal Investigator |
| Jack Sobel, M.D. | Wayne State University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Segal Institute of Clinical Research | Completed | Aventura | Florida | 33161 | United States | |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| Background | Infectious Diseases in Obstetrics and Gynecology Volume 2006 (2006), Article ID 95618, 4 pages doi:10.1155/IDOG/2006/95618 /Published results are from ARG sponsored study ARG105. | ||
| 21263351 | Derived | Hassan S, Chatwani A, Brovender H, Zane R, Valaoras T, Sobel JD. Douching for perceived vaginal odor with no infectious cause of vaginitis: a randomized controlled trial. J Low Genit Tract Dis. 2011 Apr;15(2):128-33. doi: 10.1097/LGT.0b013e3181fb4270. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| of any reported adverse events. Any adverse event, will be reported in terms |
| of severity, relationship to treatment, duration, and resolution. |
| Discovery Research, Inc. |
| Withdrawn |
| Plantation |
| Florida |
| 33324 |
| United States |
| Atlanta Women's Research Institute | Active, not recruiting | Atlanta | Georgia | 30342 | United States |
| Wayne State University, Harper Hospital | Recruiting | Detroit | Michigan | 48201 | United States |
|
| Salem Research | Recruiting | Winston-Salem | North Carolina | 27103 | United States |
|
| University of Oklahoma | Terminated | Tulsa | Oklahoma | 74104 | United States |
| Temple University Hospital | Recruiting | Philadelphia | Pennsylvania | 19140 | United States |
|
| ID | Term |
|---|---|
| D014627 | Vaginitis |
| ID | Term |
|---|---|
| D014623 | Vaginal Diseases |
| D005831 | Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D000091662 | Genital Diseases |
Not provided
Not provided